2bPrecise Announces General Availability of Precision Medicine Platform
February 20 2017 - 8:01AM
(HIMSS Booth #6045) -- 2bPrecise,
LLC today announced the general availability of its
EHR-agnostic, cloud-based precision medicine platform. The
2bPrecise solution captures and securely stores genomic data, which
it harmonizes with research knowledge and clinical information. It
then pushes the resulting insights to the point of care, enabling
the clinician to take action.
2bPrecise is now giving physicians across the country the
ability to practically apply precision medicine to diagnose and
treat their patients. National Institutes of Health and Holston
Medical Group are currently participating in early adopter
programs. By delivering understandable and actionable genomic
insights into physicians’ existing clinical workflows, the platform
enables informed decision-making in an effort to improve outcomes
and reduce costs.
“As the pace of genomic discovery continues to accelerate, the
mountain of genetic data – separated in clinical, lab or other
systems – continues to grow,” said Assaf Halevy, founder and CEO of
2bPrecise. “For patients to benefit from this expanding body of
knowledge, we need to get the relevant insights into the hands of
treating providers without disrupting their existing workflows.
2bPrecise is the last-mile solution that closes this information
gap, empowering physicians to provide the most precise care.”
A wholly owned subsidiary of Allscripts Healthcare Inc.,
2bPrecise’s vendor-neutral solution is uniquely positioned for
success. “Allscripts prides itself on its reputation for investing
in open platforms driven by entrepreneurial leaders, with the goal
of helping providers regardless of their current HCIT platform,”
said Paul Black, CEO of Allscripts. “Our support of 2bPrecise is no
exception, and we are committed to helping cultivate its innovative
approach to precision medicine; making genomic insights actionable
and accessible for providers.”
Key components of the 2bPrecise platform include:
- A genomic repository that semantically tags information from a
range of clinical and genomic sources, and that extracts meaningful
insights for providers and researchers.
- A robust knowledge hub that assembles information from a wide
range of sources, enabling providers to access the most current
clinically validated information available.
- A point of care solution that delivers actionable genomic
intelligence directly into the existing workflow.
- A research-ready framework for closed-loop research-to-care
translations that can establish the foundation for future
scientific discovery.
To learn more, visit 2bPrecise at HIMSS booth #6045.
About 2bPrecise 2bPrecise harnesses the power
of genomics and precision medicine in an effort to precisely
predict and efficiently treat each individual patient. 2bPrecise’s
EHR-agnostic, cloud-based platform captures and stores genomic data
and harmonizes it with research knowledge and clinical information.
The resulting actionable insights are then pushed into a provider’s
existing clinical workflow to facilitate decision-making at the
point of care. Learn more at
www.2bPrecisehealth.com.
About AllscriptsAllscripts
(NASDAQ:MDRX) is a leader in healthcare information technology
solutions that advance clinical, financial and operational results.
Our innovative solutions connect people, places and data across an
Open, Connected Community of Health™. Connectivity empowers
caregivers to make better decisions and deliver better care for
healthier populations. To learn more, visit
www.allscripts.com, Twitter, YouTube and It Takes A
Community: The Allscripts Blog.
Media Contact:
Danielle Johns
Aria Marketing for 2bPrecise
djohns@ariamarketing.com
617-332-9999 x241
Concetta Rasiarmos
Allscripts Public Relations
concetta.rasiarmos@allscripts.com
630-740-3152
Investors:
Seth Frank
Allscripts Vice President of Investor Relations
312-506-1213
seth.frank@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Sep 2023 to Sep 2024